P/E at 38.29 vs Industry's 37.19: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflects Confidence but Warrants Scrutiny

The P/E ratio of 38.29 for Sun Pharmaceutical Industries Ltd sits slightly above the sector average of 37.19, indicating a valuation premium of approximately 3%. This premium suggests that investors are willing to pay a bit more for the stock compared to the average pharmaceutical company, possibly due to its large-cap status and market leadership. However, the premium is not excessive, signalling a balanced market view rather than exuberance. The sector itself has seen a mixed set of results, with six companies reporting so far: four posted positive outcomes and two remained flat, with no negative results recorded. This overall sector stability supports the valuation stance but also raises the question of whether Sun Pharma can sustain its premium — previously rated Hold, what is Sun Pharmaceutical Industries Ltd's current rating?

Performance Across Timeframes: Consistent Outperformance Against Sensex

Examining the stock's returns reveals a consistent outperformance relative to the Sensex across multiple time horizons. Over one year, Sun Pharma gained 15.61%, while the Sensex declined by 4.68%. The year-to-date performance is even more striking, with the stock up 16.63% compared to the Sensex's 8.86% loss. Shorter-term returns also show strength: a 3-month gain of 10.93% versus the Sensex's 0.98%, a 1-month return of 7.68% against 1.56%, and a 1-week rise of 2.65% compared to 1.67% for the benchmark. Even the daily performance today was positive, with a 0.80% increase outpacing the Sensex's 0.02%. This steady outperformance across timeframes highlights the stock's resilience and market favour — is this momentum sustainable or a peak in the current cycle?

Moving Average Configuration: Bullish Technical Setup

The technical picture for Sun Pharmaceutical Industries Ltd is notably positive. The stock is trading above all key moving averages: 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning above short, medium, and long-term averages signals a strong upward trend and suggests broad-based buying interest. The stock has also recorded a new 52-week and all-time high of Rs. 1,999.45 today, reinforcing the bullish momentum. Additionally, it has gained for four consecutive days, accumulating a 3.01% return in this period. The opening price today matched the new high, indicating strong demand at elevated levels. This technical strength contrasts with many stocks that remain below their longer-term averages, highlighting Sun Pharma's leadership in the sector — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Context: Pharmaceuticals & Biotechnology Showing Predominantly Positive Results

The Pharmaceuticals & Biotechnology sector has delivered a largely positive set of results recently. Among six companies that have declared earnings, four reported positive outcomes while two remained flat, with no negative surprises. This sector-wide stability provides a supportive backdrop for Sun Pharmaceutical Industries Ltd. The stock’s outperformance relative to the Sensex and its premium valuation appear justified in this context, as the sector’s fundamentals remain intact. However, the sector’s mixed results also suggest that selective stock picking remains essential — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Rating Context: Previously Rated Hold, Now Reassessed

MarketsMOJO had previously assigned a Hold rating to Sun Pharmaceutical Industries Ltd. This rating was updated on 8 June 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technicals. The current Mojo Score stands at 72.0, indicating a favourable view, though the exact rating is not disclosed. The rating update coincides with the stock’s strong performance and technical breakout to new highs, suggesting that the reassessment took into account the recent positive momentum and sector dynamics. This raises the question of how the new rating aligns with the stock’s premium valuation and sustained outperformance — what is the current rating?

Conclusion: Data Reflects a Stock with Strong Momentum and Justified Valuation Premium

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical leader trading at a slight premium to its sector, supported by consistent outperformance across multiple timeframes and a robust technical setup. The stock’s position above all major moving averages and its recent all-time high reinforce the strength of its current trend. Meanwhile, the sector’s predominantly positive results provide a stable backdrop for this valuation. The reassessment of the rating from Hold to a more favourable view aligns with these factors, though the precise rating remains undisclosed. Investors may consider how the premium valuation balances with the stock’s momentum and sector context — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →